vs
Side-by-side financial comparison of AbCellera Biologics Inc. (ABCL) and CAMDEN NATIONAL CORP (CAC). Click either name above to swap in a different company.
CAMDEN NATIONAL CORP is the larger business by last-quarter revenue ($64.3M vs $44.9M, roughly 1.4× AbCellera Biologics Inc.). CAMDEN NATIONAL CORP runs the higher net margin — 34.0% vs -19.9%, a 54.0% gap on every dollar of revenue. Over the past eight quarters, AbCellera Biologics Inc.'s revenue compounded faster (112.3% CAGR vs 22.6%).
AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.
Camden National Bank is a commercial bank headquartered in Camden, Maine, operating as the principal subsidiary of Camden National Corporation, a publicly traded bank holding company. Founded in 1875, the bank became a direct, wholly owned subsidiary of the holding company following a corporate reorganization in 1984. Following the 2025 merger with Northway Financial, the combined institution has approximately $7.0 billion in assets.
ABCL vs CAC — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $44.9M | $64.3M |
| Net Profit | $-8.9M | $21.9M |
| Gross Margin | — | — |
| Operating Margin | -63.7% | — |
| Net Margin | -19.9% | 34.0% |
| Revenue YoY | 788.4% | — |
| Net Profit YoY | 73.9% | -3.0% |
| EPS (diluted) | $-0.03 | $1.29 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $64.3M | ||
| Q4 25 | $44.9M | $68.1M | ||
| Q3 25 | $9.0M | $65.4M | ||
| Q2 25 | $17.1M | $62.3M | ||
| Q1 25 | $4.2M | $60.1M | ||
| Q4 24 | $5.0M | $47.6M | ||
| Q3 24 | $6.5M | $45.0M | ||
| Q2 24 | $7.3M | $42.8M |
| Q1 26 | — | $21.9M | ||
| Q4 25 | $-8.9M | $22.6M | ||
| Q3 25 | $-57.1M | $21.2M | ||
| Q2 25 | $-34.7M | $14.1M | ||
| Q1 25 | $-45.6M | $7.3M | ||
| Q4 24 | — | $14.7M | ||
| Q3 24 | $-51.1M | $13.1M | ||
| Q2 24 | $-36.9M | $12.0M |
| Q1 26 | — | — | ||
| Q4 25 | -63.7% | 41.5% | ||
| Q3 25 | -851.8% | 40.5% | ||
| Q2 25 | -290.2% | 28.5% | ||
| Q1 25 | -1479.6% | 10.3% | ||
| Q4 24 | — | 38.7% | ||
| Q3 24 | -1439.4% | 35.2% | ||
| Q2 24 | -1276.2% | 34.7% |
| Q1 26 | — | 34.0% | ||
| Q4 25 | -19.9% | 33.1% | ||
| Q3 25 | -637.8% | 32.4% | ||
| Q2 25 | -203.3% | 22.6% | ||
| Q1 25 | -1077.2% | 12.2% | ||
| Q4 24 | — | 30.8% | ||
| Q3 24 | -785.4% | 29.1% | ||
| Q2 24 | -504.3% | 28.0% |
| Q1 26 | — | $1.29 | ||
| Q4 25 | $-0.03 | $1.33 | ||
| Q3 25 | $-0.19 | $1.25 | ||
| Q2 25 | $-0.12 | $0.83 | ||
| Q1 25 | $-0.15 | $0.43 | ||
| Q4 24 | — | $1.00 | ||
| Q3 24 | $-0.17 | $0.90 | ||
| Q2 24 | $-0.13 | $0.81 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $128.5M | — |
| Total DebtLower is stronger | — | $514.4M |
| Stockholders' EquityBook value | $966.9M | $710.0M |
| Total Assets | $1.4B | $7.0B |
| Debt / EquityLower = less leverage | — | 0.72× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $128.5M | — | ||
| Q3 25 | $83.2M | — | ||
| Q2 25 | $92.4M | — | ||
| Q1 25 | $159.3M | — | ||
| Q4 24 | $156.3M | — | ||
| Q3 24 | $126.6M | — | ||
| Q2 24 | $148.3M | — |
| Q1 26 | — | $514.4M | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $710.0M | ||
| Q4 25 | $966.9M | $696.6M | ||
| Q3 25 | $964.0M | $676.4M | ||
| Q2 25 | $1.0B | $652.1M | ||
| Q1 25 | $1.0B | $640.1M | ||
| Q4 24 | $1.1B | $531.2M | ||
| Q3 24 | $1.1B | $529.9M | ||
| Q2 24 | $1.1B | $508.3M |
| Q1 26 | — | $7.0B | ||
| Q4 25 | $1.4B | $7.0B | ||
| Q3 25 | $1.4B | $7.0B | ||
| Q2 25 | $1.4B | $6.9B | ||
| Q1 25 | $1.3B | $7.0B | ||
| Q4 24 | $1.4B | $5.8B | ||
| Q3 24 | $1.4B | $5.7B | ||
| Q2 24 | $1.4B | $5.7B |
| Q1 26 | — | 0.72× | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-34.7M | — |
| Free Cash FlowOCF − Capex | $-44.6M | — |
| FCF MarginFCF / Revenue | -99.4% | — |
| Capex IntensityCapex / Revenue | 21.9% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-174.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-34.7M | $63.9M | ||
| Q3 25 | $-52.6M | $36.1M | ||
| Q2 25 | $-32.4M | $6.0M | ||
| Q1 25 | $-11.6M | $1.0M | ||
| Q4 24 | $-108.6M | $60.9M | ||
| Q3 24 | $-28.9M | $-14.5M | ||
| Q2 24 | $-30.0M | $14.5M |
| Q1 26 | — | — | ||
| Q4 25 | $-44.6M | $58.2M | ||
| Q3 25 | $-61.5M | $35.4M | ||
| Q2 25 | $-45.8M | $4.5M | ||
| Q1 25 | $-22.2M | $-727.0K | ||
| Q4 24 | $-187.0M | $55.4M | ||
| Q3 24 | $-47.4M | $-16.2M | ||
| Q2 24 | $-50.1M | $13.2M |
| Q1 26 | — | — | ||
| Q4 25 | -99.4% | 85.5% | ||
| Q3 25 | -687.0% | 54.1% | ||
| Q2 25 | -267.9% | 7.3% | ||
| Q1 25 | -524.0% | -1.2% | ||
| Q4 24 | -3702.8% | 116.4% | ||
| Q3 24 | -728.4% | -36.0% | ||
| Q2 24 | -683.8% | 30.8% |
| Q1 26 | — | — | ||
| Q4 25 | 21.9% | 8.4% | ||
| Q3 25 | 99.7% | 1.1% | ||
| Q2 25 | 78.2% | 2.4% | ||
| Q1 25 | 251.1% | 2.9% | ||
| Q4 24 | 1552.7% | 11.7% | ||
| Q3 24 | 284.6% | 3.8% | ||
| Q2 24 | 274.6% | 3.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | 2.83× | ||
| Q3 25 | — | 1.70× | ||
| Q2 25 | — | 0.43× | ||
| Q1 25 | — | 0.14× | ||
| Q4 24 | — | 4.15× | ||
| Q3 24 | — | -1.11× | ||
| Q2 24 | — | 1.21× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ABCL
Segment breakdown not available.
CAC
| Net Interest Income | $52.4M | 81% |
| Noninterest Income | $12.0M | 19% |
